Table 1. Demographic and clinical characteristics of COPD patients.
| Characteristics | N=104 |
|---|---|
| Age (years) | 70.9±8.3 |
| Male sex, n (%) | 51 (49.0) |
| Body mass index (kg/m2) | 19.3±4.1 |
| % predicted FEV1 | 67.3±23.6 |
| Ratio of FEV1/FVC (%) | 55.2±9.4 |
| GOLD classification | |
| A | 59 (56.7) |
| B | 24 (23.1) |
| C | 13 (12.5) |
| D | 8 (7.7) |
| mMRC score, median [IQR] | 1 [1–2] |
| CAT score median [IQR] | 4 [2–8] |
| Frequent AE in the previous year (≥2 times/year) | 21 (20.2) |
| No. of AE in the previous year, median [IQR] | 1 [0–1] |
| Co-morbidity | |
| Cardiovascular disease | 44 (42.3) |
| Metabolic disease | 2 (1.9) |
| Cardiovascular + metabolic disease | 16 (15.4) |
| None | 42 (40.4) |
| Controller inhale medication | |
| SABA | 36 (34.6) |
| ICS | 10 (9.6) |
| ICS + LABA | 58 (55.8) |
| Controller device | |
| pMDI | 44 (42.3) |
| pMDI with spacer | 60 (57.7) |
Data are mean ± SD or n (%), otherwise stated. COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; mMRC, modified Medical Research Council score; CAT, COPD assessment test; GOLD, Global Initiative for Chronic Obstructive Pulmonary Disease; AE, acute exacerbation; SABA, short acting beta-2 agonist; ICS, inhale corticosteroid; LABA, long-acting beta-2 agonist; pMDI, pressurized metered-dose inhaler; IQR, interquartile range.